NeuroOne Raises Awareness of Neurological Conditions and Role of Neurosurgeons
Join us in highlighting the goals of the American Association of Neurological Surgeons’ (AANS) during Neurosurgery Awareness Month this August
NeuroOne Medical Technologies Corporation is pleased to celebrate Neurosurgery Awareness Month, help bring greater awareness to neurological conditions and share knowledge that will enlighten the public to what it means to live with and be treated for these conditions.
Neurosurgery focuses on the prevention, diagnoses, surgical treatment and rehabilitation of disorders which affect the nervous system, especially the brain, spinal cord and peripheral nerves.
Some of the many conditions that neurosurgeons treat include epilepsy, spinal disc herniation, cervical spinal stenosis, lumbar spinal stenosis, hydrocephalus, traumatic brain injury, and brain tumors and tumors of the spinal cord.
Introducing Evo™ Electrodes
We would like to also bring attention to our next-generation electrode technology, which has the potential to change the landscape of neurosurgical applications. This platform technology is based on thin-film, high-definition electrodes designed to record brain activity, ablate targeted problematic brain tissue and even stimulate parts of the nervous system for therapeutic purposes.
Evo™ Cortical Electrodes are the first electrode from the thin film platform to receive Food and Drug Administration 510(k) clearance. Evo Cortical Electrodes are thin film flexible strip and grid electrodes intended for temporary (less than 30 days) recording, monitoring and stimulation of brain tissue. This technology targets motor neuron-related diseases, such as epilepsy, Parkinson’s Disease and chronic pain—all well-established markets.
Decreasing Patient Discomfort
In addition to its potential for less invasive placement, Evo Cortical Electrodes may allow for mass production of high-density microelectrode arrays that could be customized per physician request. Additionally, the ability of microelectrodes to provide high spatial resolution may enable powerful computing techniques, such as machine learning and artificial intelligence.
In pre-clinical studies conducted by the Mayo Clinic, Evo Cortical Electrodes have demonstrated a reduction in the brain’s immunological response which should decrease patient discomfort and should reduce signal artifacts associated with the brain electrode interface.
To learn more about NeuroOne and the Evo Cortical Electrode, contact us.
Forward Looking Statements This post may contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding plans for product applications and product development, strategy, and performance of the NeuroOne’s technology. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this post and NeuroOne undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.